EIF2AK3 and glaucoma: Although there are multiple research data confirming a pivotal role of the PERK-dependent UPR signaling pathway in POAG pathogenesis, only a few studies have demonstrated that small-molecule PERK inhibitors may constitute a novel treatment strategy for glaucoma.